ZyVersa Therapeutics (ZVSA) said Tuesday that recently published data show inflammasome inhibition may protect pancreatic islet beta cells and reduce progression from obesity to insulin resistance and type 2 diabetes.
ZyVersa's Inflammasome ASC Inhibitor IC 100 aims to reduce obesity-related inflammation by inhibiting inflammasome adaptor protein ASC, the company said.
"This data supports the potential of Inflammasome ASC Inhibitor IC 100, as a key component of obesity care when added to incretins used for weight loss," the company said, adding that it plans to initiate phase 1 trials of IC 100 in mid-2025.
Shares of ZyVersa rose more than 37% in recent trading.
Price: 2.60, Change: +0.77, Percent Change: +42.02
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。